What are the antiviral dosing regimens for primary, recurrent, and suppressive treatment of genital herpes simplex in an adult with normal renal function?

Antiviral Dosing for Herpes Simplex

For primary genital herpes, treat with acyclovir 400 mg orally three times daily for 7-10 days; for recurrent episodes, use acyclovir 800 mg orally twice daily for 5 days; and for suppressive therapy, use acyclovir 400 mg orally twice daily. These are the most practical regimens based on dosing convenience and adherence 1.

Primary (First Clinical Episode) Treatment

The 1998 CDC guidelines provide multiple equivalent options for first episodes, but the most practical regimen is acyclovir 400 mg orally three times daily for 7-10 days 1. This balances efficacy with reasonable dosing frequency compared to the five-times-daily regimen.

Alternative equivalent regimens include:

• Acyclovir 200 mg orally five times daily for 7-10 days
• Famciclovir 250 mg orally three times daily for 7-10 days
• Valacyclovir 1 g orally twice daily for 7-10 days

Extend treatment beyond 10 days if healing is incomplete 1. For severe disease requiring hospitalization (disseminated infection, encephalitis, pneumonitis, hepatitis), use acyclovir 5-10 mg/kg IV every 8 hours for 5-7 days 2.

Important Caveat for Proctitis

First-episode herpes proctitis requires higher dosing: acyclovir 400 mg orally five times daily for 10 days 2, 1. This reflects the more extensive mucosal involvement.

Recurrent Episodes Treatment

The most practical regimen for recurrent episodes is acyclovir 800 mg orally twice daily for 5 days 2. This twice-daily dosing maximizes adherence while maintaining efficacy.

Alternative equivalent regimens:

• Acyclovir 400 mg orally three times daily for 5 days
• Acyclovir 200 mg orally five times daily for 5 days

Critical timing consideration: Treatment must be initiated during prodrome or within 2 days of lesion onset to provide benefit 2. Research shows that a 2-day course of acyclovir 800 mg three times daily can also be effective, significantly reducing lesion duration and viral shedding 3, though this shorter regimen is not included in the primary guidelines.

When NOT to Treat Recurrences

Most immunocompetent patients with recurrent disease do not benefit from episodic treatment because early administration is rarely feasible 2. Consider suppressive therapy instead if recurrences are frequent.

Suppressive Therapy

For daily suppression, use acyclovir 400 mg orally twice daily 2. This is the recommended first-line regimen.

Alternative regimen: Acyclovir 200 mg orally 3-5 times daily, with the goal of identifying the lowest effective dose for each patient 2.

Indications for Suppressive Therapy

Suppressive therapy is indicated for patients with six or more recurrences per year 2. It reduces recurrence frequency by at least 75% 2.

Duration and Monitoring

• Safety and efficacy documented for up to 5 years of continuous use 2, 4
• After 1 year of continuous suppression, discontinue therapy to reassess the patient's recurrence rate 2
• Long-term studies show sustained benefit, with 61% of patients recurrence-free in year three and annual recurrence rates dropping from >12 to approximately 1 per year 4

Important Limitations

• Suppressive therapy does not eliminate asymptomatic viral shedding or transmission potential 2
• Acyclovir-resistant strains may develop but have not been associated with treatment failure in immunocompetent patients 2

Special Populations

HIV-Infected and Immunocompromised Patients

• May require longer courses of therapy than standard recommendations 2
• Healing is slower and treatment failures occur more frequently
• Monitor closely for acyclovir resistance, which may necessitate alternative agents like foscarnet 2, 5, 6

Pregnant Women

Specific management during pregnancy requires specialized protocols not fully detailed in these guidelines, but the risk for neonatal infection should be explained to all patients 2, 1.

Practical Algorithm Summary

1. First episode: Start acyclovir 400 mg TID × 7-10 days (extend if not healed)
2. Recurrent episodes with <6 per year: Acyclovir 800 mg BID × 5 days (only if started early)
3. Frequent recurrences (≥6 per year): Switch to suppressive therapy with acyclovir 400 mg BID
4. Severe disease: Hospitalize and use IV acyclovir 5-10 mg/kg q8h
5. After 1 year of suppression: Stop and reassess recurrence frequency

Avoid topical acyclovir - it is substantially less effective than oral therapy and provides no improvement in systemic symptoms 2, 7.